Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details Narrative)

v3.23.3
Subsequent Events (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 13, 2023
Oct. 31, 2023
Oct. 11, 2023
Oct. 31, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Jun. 07, 2023
Dec. 31, 2022
Subsequent Event [Line Items]                    
Lease right of use asset         $ 90,918   $ 90,918     $ 139,662
Lease liabilities         93,145   93,145      
General and administrative expense         $ 19,255 $ 19,260 $ 57,614 $ 58,372    
Share-Based Payment Arrangement, Option [Member] | Common Stock [Member]                    
Subsequent Event [Line Items]                    
Issuance of stock options                 230,000  
Stock price                 $ 1.66  
General and Administrative Expense [Member]                    
Subsequent Event [Line Items]                    
General and administrative expense   $ 615                
Subsequent Event [Member]                    
Subsequent Event [Line Items]                    
Notice deficiency description     On October 11, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between August 29, 2023, to October 10, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until April 8, 2024 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A)              
Employee Benefits and Share-Based Compensation       $ 104,000            
Employment agreement description Effective November 13, 2023, the Company entered into an amendment to the employment agreement of Dr. Chris Chapman, its President and Chief Medical Officer, providing for Dr. Chapman’s annual base salary to be adjusted from five hundred thousand dollars ($500,000) (the “Full Base Salary”) to two hundred fifty thousand dollars ($250,000) in cash per annum, until payment of his Full Base Salary would no longer jeopardize the Company’s ability to continue as a going concern, as determined by the Company in its sole discretion. The amendment further provides that the remaining $250,000 of base salary per annum (the “Deferral Amount”) shall be deferred until payment of the Deferral Amount would no longer jeopardize the Company’s ability to continue as a going concern, as determined by the Company in its sole discretion, at which time the Deferral Amount may be paid, at Dr. Chapman’s election, in shares of Common Stock or in cash.                  
Implementation of directors agreement description In connection with an overall reduction in compensation paid to the Company’s directors implemented in November 2023, effective November 13, 2023, the Company entered into an amendment to the employment agreement of Christopher C. Schreiber, a Director and the Company’s former Executive Chairman, providing for Mr. Schreiber’s annual fee to be adjusted from three hundred thousand dollars ($300,000) (the “Full Fee”) to sixty thousand dollars ($60,000) in cash per annum, until payment of his Full Fee would no longer jeopardize the Company’s ability to continue as a going concern, as determined by the Company in its sole discretion. The amendment further provides that the remaining $240,000 of the fees per annum (the “Fee Deferral Amount”) shall be deferred until payment of the Fee Deferral Amount would no longer jeopardize the Company’s ability to continue as a going concern, as determined by the Company in its sole discretion, at which time the Fee Deferral Amount may be paid, at Mr. Schreiber’s election, in shares of Common Stock or in cash. The amendment also clarified that Mr. Schreiber’s title is “Director.”                  
Subsequent Event [Member] | General and Administrative Expense [Member]                    
Subsequent Event [Line Items]                    
Lease right of use asset   29,736   29,736            
Lease liabilities   $ 30,351   $ 30,351